SCHEMBL4597744

SCHEMBL4597744

CSc1nnnn1CS(=O)(=O)O

nearest known ligand 0.58

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 3/20 0.58
LMNA P02545 2/20 0.58
ALDH1A1 P00352 6/20 0.38
HSD17B10 Q99714 1/20 0.35
HTT P42858 3/20 0.34
HPGD P15428 1/20 0.34
SMN1; SMN2 Q16637 1/20 0.33
NPC1 O15118 1/20 0.33
POLB P06746 1/20 0.33
RAB9A P51151 1/20 0.33
CYP1A2 P05177 1/20 0.32
TSHR P16473 1/20 0.32
SLC6A4 P31645 1/20 0.32
CYP2C19 P33261 2/20 0.31
USP2 O75604 1/20 0.31
MEN1 O00255 1/20 0.31
NPSR1 Q6W5P4 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9334609 0.83 KMT2A (0.65) KMT2ALMNAALDH1A1HSD17B10HTT
SCHEMBL13297834 0.83 ALDH1A1 (0.47) KMT2ALMNAALDH1A1HSD17B10HTT
SCHEMBL9332182 0.82 LMNA (0.58) KMT2ALMNAALDH1A1HSD17B10HTT
SCHEMBL4597740 0.82 KMT2A (0.36) KMT2ALMNAALDH1A1HSD17B10HTT
SCHEMBL16118721 0.80 ALDH1A1 (0.53) KMT2ALMNAALDH1A1HSD17B10HTT
SCHEMBL16091099 0.79 HSD17B10 (0.43) KMT2ALMNAALDH1A1HSD17B10HTT
SCHEMBL9487028 0.76 KMT2A (0.59) KMT2ALMNAALDH1A1HSD17B10HTT
SCHEMBL10404026 0.76 ALDH1A1 (0.37) KMT2ALMNAALDH1A1HSD17B10HTT
SCHEMBL13814463 0.74 LMNA (0.31) KMT2ALMNA
SCHEMBL9602660 0.70 CYP1A2 (0.31) CYP1A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 47 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6420554-B1 REACTION OF BETA LACTAM WITH PHOSPHOROUS HALIDE IN THE PRESENCE OF BASE, ADDING PHENOL, REACTION WITH ALCOHOL AND REMOVAL OF ESTER OTSUKA KAGAKU KABUSHIKI KAISHA (JP) 2002-07-16 US claimed
US-4547573-A BACTERICIDES ICI PHARMA (FR) 1985-10-15 US claimed
US-4504478-A Cephalosporin-1-oxide derivatives IMPERIAL CHEMICAL INDUSTRIES PLC (FR) 1985-03-12 US claimed
US-4497949-A PHOTOTHERMOGRAPHY;COLOR FILMS;STORAGE STABILITY;ANTIFOGGING AGENTS IMPERIAL CHEMICAL INDUSTRIES PLC (GB) 1985-02-05 US claimed
US-4492692-A BACTERICIDE IMPERIAL CHEMICAL INDUSTRIES PLC (GB) 1985-01-08 US claimed
US-4463173-A ANTIBIOTIC, BACTERICIDE ICI PHARMA (FR) 1984-07-31 US claimed
EP-0113965-A2 Process for the preparation of cephalosporin derivatives ICI PHARMA (FR) 1984-07-25 EP claimed
EP-0031708-B1 CEPHALOSPORIN DERIVATIVES, PROCESSES FOR THEIR MANUFACTURE, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM AND INTERMEDIATES THEREFOR ICI PHARMA (FR) 1984-06-13 EP claimed
EP-0082648-A2 Cephalosporin derivatives IMPERIAL CHEMICAL INDUSTRIES PLC (GB) 1983-06-29 EP claimed
EP-0075434-A2 Cephalosporins, their preparation and their pharmaceutical compositions ICI PHARMA (FR) 1983-03-30 EP claimed
EP-0072608-A2 Process for the preparation of cephalosporin derivatives IMPERIAL CHEMICAL INDUSTRIES PLC (GB) 1983-02-23 EP claimed
EP-0055562-A2 Cephalosporin derivatives ICI PHARMA (FR) 1982-07-07 EP claimed
EP-1010701-B1 PROCESS FOR THE PREPARATION OF 3-CEPHEM COMPOUNDS OTSUKA KAGAKU KK (JP) 2008-01-16 EP disclosed
US-20070196859-A1 Novel antibacterial agents THERAVANCE BIOPHARMA ANTIBIOTICS IP, LLC 2007-08-23 US disclosed
US-20070111980-A1 Process for preparing pure cephalosporine intermediates HETERO DRUGS LIMITED (IN) 2007-05-17 US disclosed
WO-2004101572-A1 7-GLUTARYL IMIDE CEPHALOSPORANIC ACID DERIVATIVES AND PROCESS FOR PREPARING IT CKD BIO CORPORATION (KR) 2004-11-25 WO disclosed
EP-0075434-A2 Cephalosporins, their preparation and their pharmaceutical compositions ICI PHARMA (FR) 1983-03-30 EP disclosed
EP-0072608-A2 Process for the preparation of cephalosporin derivatives IMPERIAL CHEMICAL INDUSTRIES PLC (GB) 1983-02-23 EP disclosed
EP-0055562-A2 Cephalosporin derivatives ICI PHARMA (FR) 1982-07-07 EP disclosed
EP-0031708-A2 Cephalosporin derivatives, processes for their manufacture, pharmaceutical compositions containing them and intermediates therefor ICI PHARMA (FR) 1981-07-08 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070196859-A1 Novel antibacterial agents ENGASE, PEPD, PGLS KMT2A 3557/4885LMNA 3455/4885ALDH1A1 1953/4885
US-20070111980-A1 Process for preparing pure cephalosporine intermediates ACMSD, CEL, MGAM KMT2A 690/4885LMNA 1502/4885ALDH1A1 197/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.